Pegfilgrastim

Pegfilgrastim is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Brands
PEG-FILGEN
Adult Dose
Dose: 6 to 6 mg
Single Dose: 6 (6)
Frequency: As recommended.
Route: Sc
Instructions: 6 mg administered subcutaneously once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.
Neonatal
Paedriatic
Characteristics
It belongs to Granulocyte colony stimulating factor agonist pharmacological group on the basis of mechanism of action and also classified in Hematological Agents pharmacological group.
Contraindications
Pegfilgrastim is contraindicated in conditions like Hypersensitivity to the drug.
Effects
Pegfilgrastim produces potentially life-threatening effects which include Allergic reactions, Respiratory distress syndrome. which are responsible for the discontinuation of Pegfilgrastim therapy.The symptomatic adverse reactions produced by Pegfilgrastim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Myalgia, Arthralgia.
Indications
Pegfilgrastim is primarily indicated in conditions like Aplastic anemia, Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Myeloablative therapy followed by bone marrow transplantation.
Interactions
No data regarding the interactions of Pegfilgrastim was found.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Injection Do not Freeze. Protect from Sunlight and Heat.
Warnings
Fatal splenic rupture can occur. Evaluate for splenomegaly or splenic rupture in patients with left upper abdominal or shoulder pain. Acute respiratory distress syndrome (ARDS) can occur. Evaluate for ARDS in patients who develop fever, lung infiltrates, or respiratory distress. Discontinue in patients with ARDS. Serious allergic reactions, including anaphylaxis, can occur. Permanently discontinue in patients with serious allergic reactions. Severe and sometimes fatal sickle cell crises can occur.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.